Serial serum c-erbB-2 levels in patients with breast carcinoma

Cancer

Volumn 78, Issue 2, 1996, Pages 267-272

  Volas, Gena H ^a,d   Leitzel, Kim ^a   Teramoto, Yoshio ^b   Grossberg, Howard ^c   Demers, Laurence ^a   Lipton, Allan ^a,e  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b Ciba Corning Diagnostics Corp   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^e PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

breast carcinoma; c erbB 2; enzyme linked immunoadsorbent assay; hormonal therapy; serum

Indexed keywords

AROMATASE INHIBITOR; FADROZOLE; MEGESTROL ACETATE; TUMOR MARKER;

ARTICLE; BREAST CARCINOMA; BREAST METASTASIS; CANCER HORMONE THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOUBLE BLIND PROCEDURE; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ONCOGENE C ERB; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SERUM;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CARCINOMA; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FADROZOLE; FEMALE; HUMANS; MEGESTROL; MEGESTROL ACETATE; PLACEBOS; PROGNOSIS; RECEPTOR, ERBB-2; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0030017945     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960715)78:2<267::AID-CNCR12>3.0.CO;2-U     Document Type: Article

References (31)

1. Maguire HC, Green MI. The neu (c-erbB-2) oncogene. Semin Oncol 1989;16:148-55.
2. erbB2. Science 1990;249:1552-5.
3. erbB2. Science 1992;256:1205-10.
4. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mouse mammary carcinoma. Science 1985;229:974-6.
5. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
6. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990;8:103-12.
7. van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, et al. neu-protein overexpression in breast cancer: association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988;319:1239-45.
8. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989;7:1120-8.
9. Tal M, Wetzler M, Josefberg Z, Deutch A, Gutman M, Assaf D, et al. Sporadic amplification of the HER-2/neu protooncogene in adenocarcinomas of various tissues. Cancer Res 1988;48:1517-20.
10. Fontaine J, Tesseraux M, Klein V, Bastert G, Blin N. Gene amplification and expression of the neu (c-erbB-2) sequence in human mammary carcinoma. Oncology 1988;45:360-3.
11. Varley JM, Swallow JE, Brammer WJ, Whittaker JL, Walker RA. Alteration to either c-erbB-2 (neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short term prognosis. Oncogene 1987;1:423-30.
12. Zhou DJ, Ahuja H, Cline MJ. Proto-oncogene abnormalities in human breast cancer: c-erbB-2 amplification does not correlate with recurrence of disease. Oncogene 1989;4:105-8.
13. Heintz NH, Leslie KO, Rogers LA, Howard PL. Amplification of the c-erbB-2 oncogene and prognosis of breast adenocarcinoma. Arch Pathol Lab Med 1990;114:160-3.
14. Clark GM, McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 1991; 51:944-8.
15. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989;244:707-12.
16. neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 1990; 50:5184-91.
17. Hetzel DJ, Wilson TO, Keeney GL, Roche PC, Cha SS, Podratz KC. HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol 1992;47:179-85.
18. Weber W, Gill GN, Spiess J. Production of an epidermal growth factor receptor-related protein. Science 1984;224: 294-7.
19. Langton BC, Crenshaw MC, Chao LA, Stuart SG, Akita RW, Jackson JE. An antigen immunologically related to the external domain of gp 185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene. Cancer Res 1991;51:2593-8.
20. Leitzel K, Teramoto Y, Sampson E, Mauceri J, Langton B, Deniers L, et al. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J Clin Oncol 1992;10:1436-43.
21. Leitzel K, Teramoto Y, Konrad K, Chinchilli V, Volas G, Grossberg H, et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995;13:1129-35.
22. Volas GH, Leitzel K, Teramoto Y, Sampson E, Mauceri J, Demers L, et al. Serial serum c-erbB-2 levels and response in breast cancer patients [abstract]. Proc Am Assoc Cancer Res 1992;33:253.
23. Hayes DF, Cirrincione C, Carney W, Rodrigue S, Berry D, Younger J, et al. Elevated circulating HER-2/neu related protein (NRP) is associated with poor survival in patients with metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol 1993;12:58.
24. Narita T, Funahashi H, Satoh Y, Takagi H. c-erbB-2 protein in the sera of breast cancer patients. Breast Cancer Res Treat 1992;24:97-102.
25. Kynast B, Binder L, Marx D, Zoll B, Schmoll H-J, Oellerich M, et al. Determination of a fragment of the c-erbB-2 translational product p185 in serum of breast cancer patients. J Cancer Res Clin Oncol 1993;119:249-52.
26. Wu JT, Astill ME, Zhang P. Detection of the extracellular domain of c-erbB-2 oncoprotein in sera from patients with various carcinomas: correlation with tumor markers. J Clin Lab Anal 1993;7:31-40.
27. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994;54:16-20.
28. Bates SE. Clinical application of serum tumor markers. Ann Intern Med 1991;115:623-38.
29. Colomer R, Ruibal A, Salvador L. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer 1989;64:1674-81.
30. Hayes DF, Zurawaski VR, Kufe DW. Comparison of circulating CA 15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 1986;4:1542-50.
31. Tondini C, Hayes DF, Gelman R, Henderson IC, Kufe DW. Comparison of CA 15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res 1988;48:4107-12.